Phase 3 Readout
DNTH: Phase 3 Topline: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to evaLua
October 31, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- October 31, 2026
- Company
- Dianthus Therapeutics, Inc. /DE/ (DNTH)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to evaLua
- Indication
- Atrial Fibrillation (AF)